Literature DB >> 8943208

Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.

R E Atchison1, J Gosling, F S Monteclaro, C Franci, L Digilio, I F Charo, M A Goldsmith.   

Abstract

The human beta-chemokine receptor CCR5 is an important cofactor for entry of human immunodeficiency virus-type 1 (HIV-1). The murine form of CCR5, despite its 82 percent identity to the human form, was not functional as an HIV-1 coreceptor. HIV-1 entry function could be reconstituted by fusion of various individual elements derived from the extracellular region of human CCR5 onto murine CCR5. Analysis of chimeras containing elements from human CCR5 and human CCR2B suggested that a complex structure rather than single contact sites is responsible for facilitation of viral entry. Further, certain chimeras lacking the domains necessary to signal in response to their natural chemokine ligands retained vigorous HIV-1 coreceptor activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943208     DOI: 10.1126/science.274.5294.1924

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  125 in total

1.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 2.  Humanized mouse models for HIV-1 infection of the CNS.

Authors:  Jenna B Honeycutt; Patricia A Sheridan; Glenn K Matsushima; J Victor Garcia
Journal:  J Neurovirol       Date:  2014-11-04       Impact factor: 2.643

3.  Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells.

Authors:  P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120.

Authors:  Chih-chin Huang; Miro Venturi; Shahzad Majeed; Michael J Moore; Sanjay Phogat; Mei-Yun Zhang; Dimiter S Dimitrov; Wayne A Hendrickson; James Robinson; Joseph Sodroski; Richard Wyatt; Hyeryun Choe; Michael Farzan; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

Review 5.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

Review 6.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

7.  Potentiation of EBV-induced B Cell transformation by CXCR4-tropic, but not CCR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis.

Authors:  Sujatha Iyengar; David H Schwartz
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

8.  Critical role in CXCR4 signaling and internalization of the polypeptide main chain in the amino terminus of SDF-1α probed by novel N-methylated synthetically and modularly modified chemokine analogues.

Authors:  Chang-Zhi Dong; Shaomin Tian; Won-Tak Choi; Santhosh Kumar; Dongxiang Liu; Yan Xu; Xiaofeng Han; Ziwei Huang; Jing An
Journal:  Biochemistry       Date:  2012-07-23       Impact factor: 3.162

9.  Do beta-chemokines have clinical relevance in HIV infection?

Authors:  C E Mackewicz; E Barker; G Greco; G Reyes-Teran; J A Levy
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

10.  Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies.

Authors:  Shuqun Liu; Shixiu Fan; Zhirong Sun
Journal:  J Mol Model       Date:  2003-08-29       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.